SCHEMBL314167

SCHEMBL314167

Clc1ccc(CCBr)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 2/20 0.56
TDP1 Q9NUW8 1/20 0.55
MAOB P27338 1/20 0.48
IDO1 P14902 4/20 0.48
AOC3 Q16853 1/20 0.46
HTR3E A5X5Y0 1/20 0.45
HTR3B O95264 1/20 0.45
HTR3A P46098 1/20 0.45
HTR3D Q70Z44 1/20 0.45
HTR3C Q8WXA8 1/20 0.45
MIF P14174 1/20 0.45
LMNA P02545 1/20 0.44
CYP2A6 P11509 1/20 0.44
IGF1R P08069 1/20 0.43
ALOX15 P16050 1/20 0.43
SLC6A4 P31645 1/20 0.42
AGXT P21549 1/20 0.42
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
KCNH2 Q12809 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27961329 0.93 TAAR1 (0.50) TAAR1TDP1MAOBIDO1AOC3
SCHEMBL7459305 0.93 MAOB (0.59) TAAR1TDP1MAOBIDO1AOC3
SCHEMBL1396008 0.89 CA2 (0.48) TAAR1TDP1MAOBIDO1AOC3
SCHEMBL9293968 0.87 MAOB (0.48) TAAR1TDP1MAOBIGF1RALOX15
SCHEMBL2281085 0.85 TDP1 (0.71) TAAR1TDP1MAOBHTR3ACYP2A6
SCHEMBL81407 0.84 TAAR1 (0.52) TAAR1MAOBIDO1AOC3HTR3E
SCHEMBL1008937 0.82 IGF1R (0.53) TAAR1MAOBIDO1AOC3HTR3E
SCHEMBL2135113 0.82 TAAR1 (0.68) TAAR1MAOBIDO1AOC3HTR3E
SCHEMBL30932186 0.82 TDP1 (0.67) TAAR1TDP1MAOBCYP2A6MEN1
SCHEMBL7614753 0.80 KCNH2 (0.53) TAAR1MAOBIDO1HTR3EHTR3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 566 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117756843-A Preparation method of alkyl germanium based on olefin difunctional 南京信息工程大学 2024-03-26 CN claimed
CN-112358406-A Preparation method of lorcaserin intermediate 山东省药学科学院 2021-02-12 CN claimed
CN-110343197-B Preparation method and antibacterial application of polymer type quaternary ammonium salt photocatalyst 浙江大学 2020-11-06 CN claimed
CN-110343197-A A kind of preparation method and its antibacterial application of polymeric quaternary ammonium salt photochemical catalyst 浙江大学 2019-10-18 CN claimed
EP-2999692-A1 NOVEL SYNTHETIC PROCESSES TO 8-CHLORO-3-BENZO[D]AZEPINE VIA FRIEDEL-CRAFTS ALKYLATION OF OLEFIN LEK Pharmaceuticals d.d. (SI) 2016-03-30 EP claimed
CN-105295274-A Bromine-series composite flame retardant and preparation method thereof NINGXIA RUNLONG NEW PACKAGING MATERIAL CO LTD 2016-02-03 CN claimed
CN-104478670-A Preparation method of 5-bromine-2-chlorine-4'-ethyoxyl diphenylmethane UNIV CHINA PHARMA 2015-04-01 CN claimed
US-8822727-B2 Processes for the preparation of intermediates related to the 5-HT2C agonist (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine ARENA PHARMACEUTICALS, INC. (US) 2014-09-02 US claimed
EP-2518053-A1 PROCESS FOR THE PREPARATION OF 8-CHLORO-1-METHYL-2,3,4,5-TETRAHYDRO-1H-3-BENZAZEPINE Arena Pharmaceuticals, Inc. (US) 2012-10-31 EP claimed
US-8168782-B2 synthesis of lorcaserin ARENA PHARMACEUTICALS, INC. (US) 2012-05-01 US claimed
JP-2008516973-A 2008-05-22 JP claimed
WO-2007120517-A2 PROCESSES FOR THE PREPARATION OF 8-CHLORO-1-METHYL-2,3,4,5-TETRAHYDRO-1H-3-BENZAZEPINE AND INTERMEDIATES RELATED THERETO ARENA PHARMACEUTICALS, INC. (US) 2007-10-25 WO claimed
EP-1446413-A4 SYNTHESIS OF 2-ARALKOXY ADENOSINES AND 2-ALKOXYADENOSINES KING PHARMACEUTICALS RES & DEV (US) 2007-10-17 EP claimed
EP-1812439-A2 KINASE INHIBITORS Takeda San Diego, Inc. (US) 2007-08-01 EP claimed
WO-2006044687-A2 KINASE INHIBITORS TAKEDA SAN DIEGO, INC. (US) 2006-04-27 WO claimed
US-6951932-B2 Synthesis of 2-aralkoxyadenosines and 2-alkoxyadenosines KING PHARMACEUTICALS RESEARCH & DEVELOPMENT, INC. (US) 2005-10-04 US claimed
CN-1608076-A Synthesis of 2-aralkyloxyadenosine and 2-alkoxyadenosine KING PHARMACEUTICALS RES & DEV (US) 2005-04-20 CN claimed
EP-1446413-A1 SYNTHESIS OF 2-ARALKOXY ADENOSINES AND 2-ALKOXYADENOSINES King Pharmaceuticals Research and Development Inc. (US) 2004-08-18 EP claimed
US-20030199686-A1 Synthesis of 2-aralkoxyadenosines and 2-alkoxyadenosines KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. 2003-10-23 US claimed
WO-2003035662-A1 SYNTHESIS OF 2-ARALKOXY ADENOSINES AND 2-ALKOXYADENOSINES KING PHARMACEUTICALS RESEARCH & DEVELOPMENT, INC. (US) 2003-05-01 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030199686-A1 Synthesis of 2-aralkoxyadenosines and 2-alkoxyadenosines AMPD2, ADAR, ADA TAAR1 3997/4885TDP1 1617/4885MAOB 1646/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.